Patents by Inventor Christoph Boss
Christoph Boss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11839613Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: GrantFiled: May 17, 2018Date of Patent: December 12, 2023Assignee: Idorsia Pharmaceuticals LtdInventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
-
Patent number: 11712438Abstract: The present invention relates to phenyl derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: GrantFiled: May 17, 2018Date of Patent: August 1, 2023Assignee: Idorsia Pharmaceuticals LtdInventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
-
Patent number: 11446298Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: GrantFiled: May 17, 2018Date of Patent: September 20, 2022Assignee: IDORSIA PHARMACEUTICALS LTDInventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
-
Publication number: 20220259212Abstract: The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in the treatment of inter alia cancer is disclosed.Type: ApplicationFiled: July 10, 2020Publication date: August 18, 2022Inventors: Christoph BOSS, Sylvaine CREN, Thierry KIMMERLIN, Carina LOTZ-JENNE, Julien POTHIER, Naomi TIDTEN-LUKSCH
-
Patent number: 11325899Abstract: The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: GrantFiled: May 17, 2018Date of Patent: May 10, 2022Assignee: IDORSIA PHARMACEUTICALS LTDInventors: Christoph Boss, Olivier Corminboeuf, Heinz Fretz, Isabelle Lyothier, Davide Pozzi, Sylvia Richard-Bildstein, Hervé Siendt, Thierry Sifferlen
-
Patent number: 11267824Abstract: The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia cancer is disclosed.Type: GrantFiled: August 16, 2018Date of Patent: March 8, 2022Assignee: IDORSIA PHARMACEUTICALS LTDInventors: Christoph Boss, Daniel Bur, Sylvaine Cren, Thierry Kimmerlin, Carina Lotz-Jenne, Julien Pothier, Naomi Tidten-Luksch
-
Publication number: 20210395238Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.Type: ApplicationFiled: September 3, 2021Publication date: December 23, 2021Applicant: ACTELTION PHARMACEUTICALS LTDInventors: Hamed AISSAOUI, Martin BOLLI, Christoph BOSS, Sylvia RICHARD-BILDSTEIN, Patrick SIEBER
-
Patent number: 11136317Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.Type: GrantFiled: January 30, 2020Date of Patent: October 5, 2021Assignee: Actelion Pharmaceuticals LTDInventors: Hamed Aissaoui, Martin Bolli, Christoph Boss, Sylvia Richard-Bildstein, Patrick Sieber
-
Patent number: 11040966Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.Type: GrantFiled: May 7, 2019Date of Patent: June 22, 2021Assignee: IDORSIA PHARMACEUTICALS LTDInventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi Williams
-
Publication number: 20210115031Abstract: The present invention relates to benzofurane and benzothiophene derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: ApplicationFiled: May 17, 2018Publication date: April 22, 2021Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
-
Publication number: 20210113559Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: ApplicationFiled: May 17, 2018Publication date: April 22, 2021Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
-
Publication number: 20200405696Abstract: The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia the treatment of cancer is disclosed.Type: ApplicationFiled: January 14, 2019Publication date: December 31, 2020Inventors: Christoph BOSS, Sylvaine CREN, Thierry KIMMERLIN, Carina LOTZ-JENNE, Julien POTHIER, Naomi TIDTEN-LUKSCH
-
Publication number: 20200216467Abstract: The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia cancer is disclosed.Type: ApplicationFiled: August 16, 2018Publication date: July 9, 2020Inventors: Christoph BOSS, Daniel BUR, Sylvaine CREN, Thierry KIMMERLIN, Carina LOTZ-JENNE, Julien POTHIER, Naomi TIDTEN-LUKSCH
-
Publication number: 20200179383Abstract: The present invention relates to phenyl derivatives of formula (I) wherein (R1)a, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: ApplicationFiled: May 17, 2018Publication date: June 11, 2020Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
-
Publication number: 20200165235Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.Type: ApplicationFiled: January 30, 2020Publication date: May 28, 2020Applicant: ACTELION PHARMACEUTICALS LTDInventors: Hamed Aissaoui, Martin Bolli, Christoph Boss, Sylvia Richard-Bildstein, Patrick Sieber
-
Publication number: 20200108068Abstract: The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.Type: ApplicationFiled: May 17, 2018Publication date: April 9, 2020Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
-
Patent number: 10584118Abstract: The invention relates to 2,5-disubstituted benzoxazole and benzothiazole derivatives of Formula (I) wherein L, X, Y, and ring (A) are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds may be useful for the prevention or treatment of diseases or disorders associated with impaired reactive oxygen species (ROS) production, and/or for the prevention or treatment of various fibrotic diseases.Type: GrantFiled: June 21, 2016Date of Patent: March 10, 2020Assignee: ACTELION PHARMACEUTICALS LTDInventors: Hamed Aissaoui, Martin Bolli, Christoph Boss, Sylvia Richard-Bildstein, Patrick Sieber
-
Publication number: 20190263797Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.Type: ApplicationFiled: May 7, 2019Publication date: August 29, 2019Applicant: IDORSIA PHARMACEUTICALS LTDInventors: Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Jodi Williams
-
Patent number: 10351560Abstract: The invention relates to a crystalline form of (S)-2-(8-((5-chloropyrimidin-2-yl)(methyl)amino)-2-fluoro-6,7,8,9-tetrahydro-5H-pyrido[3,2-b]indol-5-yl)acetic acid, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as CRTH2 receptor modulators.Type: GrantFiled: September 14, 2016Date of Patent: July 16, 2019Assignee: IDORSIA PHARMACEUTICALS LTDInventors: Hamed Aissaoui, Christoph Boss, Patrick Bouis, Julien Hazemann, Romain Siegrist, Markus Von Raumer
-
Patent number: 10329287Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.Type: GrantFiled: July 7, 2017Date of Patent: June 25, 2019Assignee: IDORSIA PHARMACEUTICALS LTDInventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams